Prospective observational study to investigate the relationships between pharmacokinetics and therapeutic efficacy and adverse effect of Janus kinase inhibitor in rheumatoid arthritis.

Prospective observational study to investigate the relationships between pharmacokinetics and therapeutic efficacy and adverse effect of Janus kinase inhibitor in rheumatoid arthritis. - Prospective observational study to investigate the relationships between pharmacokinetics and therapeutic efficacy and adverse effect of Janus kinase inhibitor in rheumatoid arthritis.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000048381

Enrollment

100

Registered

2022-07-15

Start date

2022-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid arthritis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Those who take a Janus kinase inhibitor for at least seven days Those who provided a written consent to participate in the study or whose family provided a written consent to participate in the study

Exclusion criteria

Exclusion criteria: Those who the doctor in charge deems inappropriate Those who do not agree to participate

Design outcomes

Primary

Measure	Time frame
Plasma concentration of Janus kinase inhibitors	—

Countries

Japan

Contacts

Public ContactYasuaki Mino

Hamamatsu University School of Medicine Department of Hospital Pharmacy

minoy@hama-med.ac.jp053-435-2623

Outcome results